SCHEMBL1892013

SCHEMBL1892013

CCCCc1nc2[nH]c(=O)n(C)c(=O)c2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
CYP2C19 P33261 2/20 0.48
CYP3A4 P08684 2/20 0.48
ADORA2B P29275 6/20 0.47
ADORA2A P29274 3/20 0.47
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3848063 0.85 ADORA2B (0.60) POLBADORA2BADORA2AMEN1KMT2A
SCHEMBL10432472 0.83 ALDH1A1 (0.60) POLBCYP2C19CYP3A4ADORA2BADORA2A
SCHEMBL8571170 0.82 CYP3A4 (0.49) POLBCYP2C19CYP3A4ADORA2BADORA2A
SCHEMBL59950 0.77 ADORA2B (0.48) POLBCYP2C19CYP3A4ADORA2BADORA2A
SCHEMBL9406540 0.76 POLB (0.83) POLBCYP2C19CYP3A4ALDH1A1CYP1A2
SCHEMBL2958489 0.76 ADORA2B (0.58) POLBCYP2C19ADORA2BADORA2AKDM4E
SCHEMBL9414260 0.76 PARP1 (0.43) POLBCYP2C19CYP3A4KDM4EMEN1
SCHEMBL9845191 0.74 XDH (0.40) POLBCYP2C19CYP3A4ALDH1A1MAPK1
SCHEMBL21935452 0.74 ADORA2B (0.54) CYP3A4ADORA2BADORA2AKDM4EMEN1
SCHEMBL6233162 0.73 XDH (0.51) ADORA2BALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875126-B1 ERYTHROID PRODUCTION THE COMMON SERVICES AGENCY (GB) 2018-01-17 EP claimed
US-20150203818-A1 ERYTHROID PRODUCTION UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2015-07-23 US claimed
EP-2875126-A1 ERYTHROID PRODUCTION The Common Services Agency (GB) 2015-05-27 EP claimed
WO-2014013255-A1 ERYTHROID PRODUCTION THE COMMON SERVICES AGENCY (GB) 2014-01-23 WO claimed
WO-2009131948-A2 HIGH-THROUGHPUT CELL-BASED CFTR ASSAY INSTITUTE FOR ONEWORLD HEALTH (US) 2009-10-29 WO claimed
EP-0956855-B1 Immunosuppressive effects of 8 substituted xanthine derivatives LEUVEN K U RES & DEV (BE) 2003-03-12 EP claimed
EP-0956855-A1 Immunosuppressive effects of 8-substituted xanthine derivatives K.U. Leuven Research & Development (BE) 1999-11-17 EP claimed
US-20250283041-A1 METHODS FOR PRODUCING RED BLOOD CELLS ALBERT EINSTEIN COLLEGE MEDICINE (US) 2025-09-11 US disclosed
EP-4532693-A1 METHODS FOR PRODUCING RED BLOOD CELLS Albert Einstein College of Medicine (US) 2025-04-09 EP disclosed
EP-4401833-A1 GPR52 MODULATOR COMPOUNDS Nxera Pharma UK Limited (GB) 2024-07-24 EP disclosed
WO-2023230405-A1 METHODS FOR PRODUCING RED BLOOD CELLS ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2023-11-30 WO disclosed
EP-4204408-A1 GPR52 MODULATOR COMPOUNDS Heptares Therapeutics Limited (GB) 2023-07-05 EP disclosed
WO-2023041909-A1 GPR52 MODULATOR COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2023-03-23 WO disclosed
WO-2005118779-A1 METHOD FOR PRODUCING PLURIPOTENT CELLS FROM MONOCYTES UNIV GOETTINGEN GEORG AUGUST (DE) 2005-12-15 WO disclosed
US-5470579-A Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation LVMH, RECHERCHE (FR) 1995-11-28 US disclosed
EP-0535038-A4 MAMMALIAN ADIPOGENIC FACTORS 1993-12-29 EP disclosed
EP-0535038-A1 MAMMALIAN ADIPOGENIC FACTORS W. ALTON JONES CELL SCIENCE CENTER (US) 1993-04-07 EP disclosed
WO-1991018924-A1 MAMMALIAN ADIPOGENIC FACTORS W. ALTON JONES CELL SCIENCE CENTER (US) 1991-12-12 WO disclosed
EP-0308460-A1 A COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION. PHARMACIA AB (SE) 1989-03-29 EP disclosed
WO-1988007380-A1 A COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION PHARMACIA AB (SE) 1988-10-06 WO disclosed